Orion Oyj (OTCMKTS:ORINY) Sets New 1-Year High – Here’s What Happened

Orion Oyj (OTCMKTS:ORINY) shares reached a new 52-week high on Thursday . The stock traded as high as $31.10 and last traded at $31.10, with a volume of 706 shares traded. The stock had previously closed at $30.48.

Analyst Upgrades and Downgrades

Separately, Nordea Equity Research cut shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Price Performance

The firm has a market capitalization of $8.78 billion, a price-to-earnings ratio of 24.68 and a beta of 0.25. The firm has a fifty day moving average price of $28.41 and a 200 day moving average price of $25.83. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25.

Orion Oyj (OTCMKTS:ORINY) last announced its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $463.41 million during the quarter. Sell-side analysts anticipate that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The business also recently declared a dividend, which will be paid on Tuesday, April 29th. Investors of record on Monday, April 7th will be issued a $0.4478 dividend. The ex-dividend date of this dividend is Monday, April 7th. This is a positive change from Orion Oyj’s previous dividend of $0.24. Orion Oyj’s dividend payout ratio (DPR) is currently 24.00%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.